Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Grip strength decreased? 1,368 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 1,368 reports of Grip strength decreased have been filed in association with INFLIXIMAB (Renflexis). This represents 1.0% of all adverse event reports for INFLIXIMAB.

1,368
Reports of Grip strength decreased with INFLIXIMAB
1.0%
of all INFLIXIMAB reports
838
Deaths
1,091
Hospitalizations

How Dangerous Is Grip strength decreased From INFLIXIMAB?

Of the 1,368 reports, 838 (61.3%) resulted in death, 1,091 (79.8%) required hospitalization, and 879 (64.3%) were considered life-threatening.

Is Grip strength decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 1,368 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Grip strength decreased?

ADALIMUMAB (2,317) METHOTREXATE (2,271) ETANERCEPT (2,018) RITUXIMAB (1,597) TOCILIZUMAB (1,537) LEFLUNOMIDE (1,492) HYDROXYCHLOROQUINE (1,476) DICLOFENAC (1,473) SULFASALAZINE (1,409) SECUKINUMAB (1,408)

Which INFLIXIMAB Alternatives Have Lower Grip strength decreased Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Grip strength decreased Reports All Drugs Causing Grip strength decreased INFLIXIMAB Demographics